BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33074351)

  • 1. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
    Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
    Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases.
    Liao L; Sun H; He J; Liu Y; Pan Z; Wu X; Fan W; Peng J; Li C
    BMC Surg; 2023 Sep; 23(1):271. PubMed ID: 37689651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?
    Hirokawa F; Asakuma M; Komeda K; Shimizu T; Inoue Y; Kagota S; Tomioka A; Uchiyama K
    Surg Today; 2019 Jan; 49(1):82-89. PubMed ID: 30255329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
    Andreou A; Gloor S; Inglin J; Di Pietro Martinelli C; Banz V; Lachenmayer A; Kim-Fuchs C; Candinas D; Beldi G
    Surg Oncol; 2021 Sep; 38():101631. PubMed ID: 34298267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases.
    Ninomiya M; Emi Y; Motomura T; Tomino T; Iguchi T; Kayashima H; Harada N; Uchiyama H; Nishizaki T; Higashi H; Kuwano H
    Int J Clin Oncol; 2021 Dec; 26(12):2255-2264. PubMed ID: 34519930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis.
    Ono K; Abe T; Oshita A; Sumi Y; Yano T; Okuda H; Kurayoshi M; Kobayashi T; Ohdan H; Noriyuki T; Nakahara M
    World J Surg Oncol; 2021 Apr; 19(1):97. PubMed ID: 33820549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study.
    Hirokawa F; Ueno M; Nakai T; Kaibori M; Nomi T; Iida H; Tanaka S; Komeda K; Hayami S; Kosaka H; Hokuto D; Kubo S; Uchiyama K
    J Gastrointest Surg; 2022 Apr; 26(4):772-781. PubMed ID: 34664190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases.
    Ruzzenente A; Bagante F; Ratti F; Beal EW; Alexandrescu S; Merath K; Makris EA; Poultsides GA; Margonis GA; Weiss MJ; Popescu I; Aldrighetti L; Guglielmi A; Pawlik TM
    HPB (Oxford); 2019 Sep; 21(9):1230-1239. PubMed ID: 30792047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
    Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
    J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.
    Sasaki K; Morioka D; Conci S; Margonis GA; Sawada Y; Ruzzenente A; Kumamoto T; Iacono C; Andreatos N; Guglielmi A; Endo I; Pawlik TM
    Ann Surg; 2018 Jan; 267(1):132-141. PubMed ID: 27763897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study.
    Ueno M; Komeda K; Kosaka H; Nakai T; Nomi T; Iida H; Tanaka S; Ikoma H; Matsuda K; Hirokawa F; Matsumoto M; Hokuto D; Mori H; Morimura R; Kaibori M; Yamaue H; Kubo S
    Int J Surg; 2021 Oct; 94():106106. PubMed ID: 34536602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of margin status and tumour burden determines survival after resection of colorectal liver metastases: A retrospective cohort study.
    Mao R; Zhao JJ; Bi XY; Zhang YF; Li ZY; Zhou JG; Zhao H; Cai JQ
    Int J Surg; 2018 May; 53():371-377. PubMed ID: 29229309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study.
    Kitano Y; Ono Y; Kobayashi K; Oba A; Sato T; Ito H; Inoue Y; Shinozaki E; Yamaguchi K; Saiura A; Baba H; Takahashi Y
    HPB (Oxford); 2024 Feb; 26(2):282-290. PubMed ID: 37985325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D; Hollande F; Michael M; Hayes I; Heriot A; Knowles B; Thomson B
    ANZ J Surg; 2021 Jun; 91(6):1196-1202. PubMed ID: 33543551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis.
    Chen FL; Wang YY; Liu W; Xing BC
    Front Oncol; 2022; 12():973418. PubMed ID: 36132151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?
    Bernardi L; Roesel R; Aghayan DL; Majno-Hurst PE; De Dosso S; Cristaudi A
    Cancer Treat Rev; 2024 Mar; 124():102696. PubMed ID: 38335813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of recurrence timing and tumor burden score on overall survival among patients undergoing repeat hepatectomy for colorectal liver metastases.
    Endo Y; Rueda BO; Woldesenbet S; Munir MM; Lima HA; Katayama ES; Shaikh CF; Guglielmi A; Ruzzenente A; Aldrighetti L; Alexandrescu S; Kitago M; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Surg Oncol; 2023 Sep; 128(4):560-568. PubMed ID: 37195231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC).
    Gawdi R; Valenzuela CD; Moaven O; Stauffer JA; Del Piccolo NR; Cheung T; Corvera CU; Wisneski AD; Cha C; Russell G; Zarandi N; Dourado J; Shen P
    J Surg Oncol; 2022 Aug; 126(2):339-347. PubMed ID: 35429409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.